GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (AQSE:BVXP.GB) » Definitions » Institutional Ownership

Bioventix (AQSE:BVXP.GB) Institutional Ownership : 24.50% (As of May. 31, 2024)


View and export this data going back to . Start your Free Trial

What is Bioventix Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bioventix's institutional ownership is 24.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bioventix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bioventix's Float Percentage Of Total Shares Outstanding is 0.00%.


Bioventix Institutional Ownership Historical Data

The historical data trend for Bioventix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix Institutional Ownership Chart

Bioventix Historical Data

The historical data trend for Bioventix can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 26.58 26.51 28.38 25.48 25.04 24.98 24.70 24.65 24.50 24.50

Bioventix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Bioventix (AQSE:BVXP.GB) Business Description

Traded in Other Exchanges
Address
East Street, 7 Romans Business Park, Farnham, Surrey, GBR, GU9 7SX
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.

Bioventix (AQSE:BVXP.GB) Headlines

No Headlines